Prof. Alberto Danielli will showcase pioneering research on the application of bacteriophage biotechnology in oncology, bridging the gap between fundamental science and clinical applications.
His talk will explore how engineered phages can revolutionize cancer therapy through drug delivery, tumor targeting, and immunomodulation.
Key Topics:
- Phage Display for Cancer Cell Targeting
- Engineering bacteriophages to selectively bind tumor-specific antigens.
- Developing phage-based nanocarriers for precision oncology.
- Bacteriophage-Based Drug Delivery & Gene Therapy
- Utilizing phage-derived vectors for targeted drug transport in solid tumors.
- Integrating phages with CRISPR-based strategies to enhance treatment efficacy.
- Oncolytic and Immunomodulatory Phage Therapy
- Investigating the oncolytic potential of phages in tumor environments.
- Leveraging bacteriophages to stimulate anti-tumor immunity and reshape the tumor microenvironment.
- Clinical Translation of Phage Biotechnology
- Preclinical and translational studies evaluating safety and efficacy.
- Challenges in regulatory approval and integration into clinical oncology.
Sigificant & Impact :
This presentation will illustrate how phage biotechnology can contribute to cancer treatment, offering targeted therapies with minimized side effects. Prof. Danielli will also discuss future directions in integrating synthetic biology, nanotechnology, and immunotherapy into phage-based platforms, opening new frontiers in precision oncology.
Targeting Phage Therapy 2025
June 10-11, 2025 – Berlin, Germany